Related Experiment Video

Updated: Oct 2, 2026

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
10:02

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma

Published on: June 2, 2023

Beta-blockers and heart failure: meta-analysis of mortality trials

T J Cleophas1, A H Zwinderman

  • 1European College of Pharmaceutical Medicine, Lyon, France. ajm.cleophas@wxs.nl

International Journal of Clinical Pharmacology and Therapeutics
|September 21, 2001
PubMed
Abstract

Insights

Beta-blockers significantly reduce all-cause and sudden cardiac deaths in heart failure patients, primarily by preventing fatal arrhythmias. They do not impact death from heart failure progression, but adverse effects are comparable to placebo.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-blockers are used in heart failure patients, with mortality as a key endpoint.
  • Previous studies may have been underpowered to analyze specific causes of death.

Purpose of the Study:

  • To assess the impact of beta-blockers on all-cause mortality, sudden death, heart failure progression deaths, and adverse effects.
  • To calculate hazard ratios for these outcomes.

Main Methods:

  • Pooled analysis of four large double-blind placebo-controlled studies.
  • Evaluation of hazard ratios for different death types and treatment discontinuation due to adverse events.

Main Results:

  • Beta-blockers significantly reduced all-cause deaths by 35% (p < 0.0001) and sudden deaths by 37% (p < 0.0001).
  • A small, non-significant 13% risk reduction was observed for death due to heart failure progression.
  • Serious adverse effects leading to discontinuation were not significantly different between beta-blocker and placebo groups.

Conclusions:

  • Beta-blockers are effective in reducing fatal arrhythmias but do not prevent death from heart failure progression.
  • The safety profile of beta-blockers is comparable to placebo.
  • Treatment with beta-blockers is recommended due to their benefits in reducing cardiac mortality.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of &#946;-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...